Lamya Shihabuddin

Lamya Shihabuddin is a seasoned professional in drug discovery and development, currently serving as Chief Scientific Officer at Montai Therapeutics and 4:59 NewCo, a 5AM Ventures Company. Additionally, Lamya is a member of the Scientific Advisory Board at Coave Therapeutics and has held significant roles at Sanofi, including Head of Research for Genetic Neurologic Diseases and Neuroinflammation & Repair. Lamya's academic background includes a Doctor of Philosophy (PhD) in Neurobiology and Neurosciences from the University of Miami Miller School of Medicine and a Master of Science in Neuroscience from the American University of Beirut.